38 ayurvedic formulations identified for 8 disease conditions

38 ayurvedic formulations identified for 8 disease conditions under Golden Triangle scheme

Thursday, September 03, 2009 08:00 IST
Joseph Alexander, New Delhi

As many as 38 ayurvedic formulations have been identified for eight disease conditions and 20 of them have been provided to CSIR for pre-clinical studies so far under the Golden Triangle Partnership scheme set up for validation of traditional ayurvedic drugs and development of new drugs.

The CSIR has submitted the status report of 10 formulations. They are tagradi kwatha (insomnia), medhya (ADHD), ashwagandha churna (anxiety neurosis), haritkyadi churna (dyslipidemia), GTP-HN-1 (hyper tension), brahmi ghrita (ADHD), gokshuradi guggulu (BPH), lakshadi guggulu (osteoporosis), nirgundi tail (joint disorders) and singhanada guggulu (joint disorders).The pre-clinical studies of all other formulations were under progress in different institutions now, sources in the Ayush department said.

The scheme was set up as an integrated technology mission for scientific validation of traditional medicines for identified disease conditions for which the apex organizations like Department of Ayush, Central Council for Research in Ayurveda and Siddha, CSIR and ICMR have joined hands. The objective of the scheme is to bring safe, effective and standard Ayurveda, Siddha, Homoeopathy and Unani products and develop new drugs of national and global importance. The apex bodies also collaborate with other institutions and companies with this purpose.

"The project is going well and more new collaborations are in the offing. The idea is to bridge the gap between modern medicine and traditional medicine so that India can tap the vast potential in the arena. It is the triangle being built between modern science, modern medicine and traditional medicine, giving a golden opportunity to the country," an official explained.

The CCRAS has also collected the inputs for protocols of different diseases and submitted to the ICMR for further revision. The draft protocols of hypertension, dyslipidemia, HIV/AIDS, osteoporosis and rheumatoid arthritis were thus given to the ICMR.

Source: PharmaBiz